-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Vinicius Ernani, MD
Vinicius Ernani has been appointed Assistant Professor at the Fred and Pamela Buffett Cancer Center of the University of Nebraska, Omaha, NE. Previous to this appointment, Dr. Ernani completed a hematology/oncology fellowship at Emory University, Atlanta, US.
-
Breaking News Briefs
• The global, randomized phase III ALEX study was announced to have met its primary endpoint, demonstrating that alectinib (Alecensa), as an initial (first-line) treatment, significantly reduced the risk of disease worsening or death (progression-free survival) compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This is the…
-
Innovations in the 8th Edition of the TNM Classification of Lung Cancer Enhance Prognostic Capabilities
Posted: April 2017 By Cynthia L. Kryder, MS, CCC-Sp, with Ramón Rami-Porta, MD Clinicians around the world began implementing the 8th edition of the tumor, node, and metastasis (TNM) classification of lung cancer on January 1, 2017. There has been confusion, however, over when the 8th edition of the TNM staging system will be fully…
-
Efforts Aim to Make Clinical Trial Information More Accessible
Posted: February 2017 By Cynthia L. Kryder, MS Clinical trials are essential to the development of new, potentially lifesaving therapies for patients with cancer. Well-designed clinical trials contribute to medical advances and evidence-based medicine. Nevertheless, the Cancer Research Institute estimates that only 3% to 6% of patients with cancer who are eligible for clinical trials…
-
Role of Nurses in the Care of Patients with Lung Cancer
Posted: February 2017 By Lori Alexander, MTPW, ELS, MWC WCLC 2016 offered focused education for nurses and allied health professionals through its nursing track, as well as through special nursing workshops held before the official start of the conference. The sessions addressed a range of topics, including the use of technology and social media, preparing…
-
A Life in Thoracic Oncology – Reflections from Giants on Milestones in the Treatment Advances in Lung Cancer
Posted: February 2017 By Lori Alexander, MTPW, ELS, MWC The closing plenary session at IASLC WCLC 2016 featured several highly regarded oncologists who have devoted the greater part of their careers to thoracic oncology. These “giants” reflected on their work and the changes they have seen in the key areas of chemotherapy, thoracic surgery, radiation…
-
Drug Approval Processes Around the World: Focus on China
Posted: February 2017 By Caicun Zhou, MD As part of an ongoing series, IASLC Lung Cancer News is exploring how drug approval processes differ country by country, and continent by continent. In China, the drug registration process includes the following steps: • Application to the China Food and Drug Administration (CFDA) for clinical trial approval,…
-
The Fourth IASLC Screening Strategy Advice Committee CT Screening Workshop
Posted: February 2017 By John K. Field, PhD, FRCPath, and James L. Mulshine, MD, PhD The Fourth IASLC Screening Strategy Advice Committee (SSAC) computed tomography (CT) screening workshop was held on December 3, 2016, prior to IASLC WCLC 2016. This workshop provided a comprehensive international forum for all lung cancer clinical specialties to meet and…
-
Impact of Clinical Pathways on Lung Cancer Management
Posted: February 2017 Q&A with with Ronan J. Kelly, MB BCh, MBA Q: What is the impetus for the development of clinical pathways? A: The incidence of cancer in the US is expected to increase by 45% in the next 2 decades, from 1.6 million in 2010 to 2.3 million in 2030. Direct medical costs associated…
-
Breaking News Briefs
Alectinib (Alecensa) received a positive opinion from the European Medicines Agency (EMA) for Medicinal Products for Human Use (CHMP) for the treatment of adult patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib. Based on this positive CHMP recommendation, a final decision is expected…